<DOC>
	<DOCNO>NCT00521482</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety intensive dose temozolomide treatment alone parallel combination thalidomide patient recurrent glioblastoma standard therapy . In treatment arm A study investigate whether continuous dose temozolomide may overcome alkylator resistance patient glioblastoma progress 5/28 day dose regimen . For treatment arm B postulate combination thalidomide temozolomide effective respect time progression progression-free survival due fact temozolomide thalidomide different mechanism action .</brief_summary>
	<brief_title>Temozolomide vs. Temozolomide Thalidomide Treatment Recurrent Glioblastoma</brief_title>
	<detailed_description>- Primary objective : To determine proportion patient progression- free survival 6 month intensive dose temozolomide treatment alone combination thalidomide patient recurrent glioblastoma multiforme standard therapy . - Secondary objective : To assess effect tumor growth . To determine time disease progression . To determine proportion patient progression- free survival . To assess safety intensive dose temozolomide treatment alone combination thalidomide . - Explorative evaluation : To assess health relate Quality Life . To assess cognitive functioning . To compare two treatment arm term efficacy safety .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Male female patient 18 70 year 2 . Histologically proven glioblastoma , WHO grade IV 3 . Evidence tumor recurrence progression MRI least 3 month radiation treatment 4 . Prior radiation treatment 60 Gy 2Gy fraction ; concurrent daily temozolomide 75 mg/m2 daily 42 day ( max . 49 day ) ; adjuvant temozolomide 150 200mg/m2 5 day 28day cycle ( max . 6 cycle ) 5 . Patient receive minimum 2 cycle adjuvant chemotherapy temozolomide concomitant regime temozolomide Radiotherapy 6 . Patient recover effect surgery 7 . Karnofsky Performance Status ≥70 8 . MiniMental State Examination score &gt; 25 9 . Adequate hepatic function : AST &lt; 52 U/l , ALT &lt; 50 U/l , AP ≤129 U/l 10 . Adequate hematological value : neutrophil ≥1.5 x 109/l , thrombocyte ≥100 x 109/l 11 . Adequate renal function : clearance &lt; 110 μmol/l 12 . Written inform consent enter study 1 . Other severe underlie disease 2 . Significant renal , hepatic bone marrow impairment 3 . Pregnant woman , woman breast feeding , woman childbearing potential use chemical mechanical contraception ( prescription oral contraceptive , abstinence , condom spermicide , surgical sterilization , diaphragm spermicide , intrauterine device ) positive pregnancy test 4 . Known Acquired Immune Deficiency Syndrome ( AIDS ) 5 . Known hypersensitivity temozolomide , dacarbazine thalidomide ( excipients ) 6 . Any concomitant drug contraindicate use temozolomide ( accord product information Swiss drug compendium ) thalidomide ( investigator 's brochure , international product information ) . 7 . Concurrent treatment experimental drug anticancer therapy ; treatment within clinical trial within 30 day prior trial entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>recurrent</keyword>
	<keyword>standard therapy</keyword>
</DOC>